Company intelligence / Profile preview

Immunovant Sciences GmbH

Basel, Basel-Stadt, Switzerland

Ownership: Private
Development stage: Other

Overview

Immunovant Sciences GmbH is a clinical-stage biopharmaceutical company primarily focused on developing monoclonal antibodies targeting the neonatal Fc receptor (FcRn) for autoimmune diseases. Current programs are advancing in Phase 2 and Phase 3 trials across multiple autoimmune indications, with clinical readouts expected in 2027 and 2028. The company is advancing compounds that may offer differentiated profiles in diseases such as Graves' disease, rheumatoid arthritis, and cutaneous lupus erythematosus, positioning to become first or best in class in select indications. No drug approvals have been reported to date.

Therapeutic areas: ImmunologyNeurologyEndocrinology
Modalities: Monoclonal antibodyBiologic
Industry: Biotech

Beyond the preview

Go deeper on Immunovant Sciences GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunovant Sciences GmbH.

Explore the full profile